VistaGen Therapeutics, Inc. (VSTA) Business Strategy Centers on Cutting-Edge Stem Cell Technology

VistaGen Therapeutics employs the expertise of company co-founder and renowned Canadian stem cell scientist Dr. Gordon Keller, as well as co-founder, president, and chief scientific officer Dr. Ralph Snodgrass.

Human Clinical Trials in a Test Tube™, the company’s human pluripotent stem cell (hPSC) technology platform, was developed using a combination of proprietary and exclusively licensed hPSC technologies, including those originating from two decades of research by Drs. Keller and Snodgrass.

The platform’s underlying technologies enable controlled differentiation of hPSCs into mature human cells specific to VistaGen’s current and potential predictive toxicology, drug metabolism, drug rescue, and regenerative cell therapy programs and commercial programs.

Utilizing these technologies, VistaGen is currently developing CardioSafe 3D™, a novel biological assay system that uses mature human heart cells derived from hPSCs to screen for heart toxicity in connection with the company’s drug rescue activities; LiverSafe 3D™, for predicting liver toxicity and metabolism issues in connection with the company’s drug rescue activities; and AV-101, a novel, orally available prodrug candidate focused on the treatment of neuropathic pain, depression, and potentially other neurological conditions.

VistaGen’s overarching goal is to combine its hPSC technology with medicinal chemistry to generate new, proprietary, chemical variants of small molecule drug candidates that were shelved due to unexpected heart or liver safety concerns.

The company believes its Human Clinical Trials in a Test Tube™ platform enables a more rapid and precise safety profile of drug rescue variants, allowing the company to generate a pipeline of drug rescue variants that it will license or sell to biotechnology and pharmaceutical companies that can further develop the products and bring them to market.

For more information, visit www.vistagen.com

Let us hear your thoughts: VistaGen Therapeutics, Inc. Message Board

Leave a Reply

You must be logged in to post a comment.